Today we announced that we have submitted an application to
Coronavirus
Today we announced that we have submitted an application to the U.S. Food and Drug Administration for review of our Spikevax 2025-2026 formula, a COVID-19 vaccine targeting the SARS-CoV-2 variant LP.8.1. Read more: https://t.co/y1ug5Ir8iE. https://t.co/VlmMxGWOVm
din zilele anterioare